Type C Meeting with US FDA set for December 11, 2025 to address key items following August 27, 2025 End of Phase 2 Meeting ...
Today, in honor of Pulmonary Hypertension Awareness Month, the American Lung Association, with support from Merck, launched a ...
Savara advances BLA plans with strong molgramostim data, large aPAP market potential, and a reinforced cash position. Find ...
NEW YORK - On Monday, OS Therapies Inc. (NYSE:OSTX) reported a wider third quarter loss as it prepares for regulatory filings for its lead candidate OST-HER2 in osteosarcoma. The company posted a net ...
InvestorsHub on MSN
OS Therapies shares slip 5% after deeper Q3 loss tied to regulatory push
OS Therapies Inc. (AMEX:OSTX) reported a larger third-quarter loss on Monday as the biotech moves into a heavier phase of ...
Received FDA IND clearance to evaluate CDI-988 as both norovirus preventive and treatmentExpects to initiate CDI-988 Phase 1b ...
AFP - Fact Check on MSN
Experts caution against 'CO2' breathing therapy promoted online
Health and wellness influencers are advertising carbon dioxide inhalers as treatment for an array of medical conditions in ...
A three-month program of resistance exercise can help improve the physical and mental well-being of people with long COVID, ...
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...
Survivors of severe COVID-19 may exhibit immune dysregulation, characterised by reduced naïve and increased senescent and ...
Live Science on MSN
New drug could prevent diabetes complications not fixed with blood sugar control, study hints
An experimental drug compound could be a promising treatment for harmful diabetes complications, per a new study in lab mice ...
Remembering her time as a cheerleader helps columnist Caroline Gainer adjust to the long game of COPD as part of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback